Clinical pharmacology of dichlorvos.
Polyvinyl resin formulation pellets (V-3 and V-12) containing dichlorvos were administered to male volunteers in single doses up to 32 mg/kg and repeated doses up to 16 mg/kg/day for up to three weeks. The cholinesterase activity depressions following single doses were dose related. Following multiple doses, the plasma cholinesterase activity was maximally depressed at all dose levels and the RBC cholinesterase activity depression was dose related.